SOURCE: OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals, Inc.

July 06, 2016 09:36 ET

OncBioMune Research Shows Activity of PGT Technology in a Mammary Cancer Animal Model

BATON ROUGE, LA--(Marketwired - July 06, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to inform shareholders of results of pre-clinical research that support further development of the Company's patented, novel paclitaxel gallium transferrin (PGT) technology for the treatment of multiple types of cancer.

OncBioMune first tested PGT against a series of human cell lines to evaluate activity in models of breast, colon, lung and three human cell lines of ovarian cancer, including a drug-resistant ovarian cancer model. The results showed PGT to act as an inhibitor of all tumor cell lines, including the drug-resistant ovarian cancer model.

OncBioMune then conducted research to develop an animal model to evaluate the activity of PGT and selected the 4T1 murine mammary carcinoma tumor model. The 4T1 murine mammary carcinoma is recognized as one of the most aggressive cancer cell lines and is known to rapidly metastasize to sites similar to human breast cancer. OncBioMune developed its own 4T1 mouse model and showed an intraperitoneal injection of PGT worked as an inhibitor of 4T1 mammary tumors. Importantly, no gross organ toxicities at necropsy were observed.

"These early studies demonstrated that our PGT technology has a wide spectrum of activity against several difficult to treat cancers," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "The data warrants additional research as we continue to widen our pipeline with cancer drug candidates. We are pleased with all the data and particularly impressed with the results in the drug-resistant ovarian cancer cell line. We believe there are several opportunities to explore FDA pathways to expedite development for this indication."

OncBioMune's PGT technology is being developed to overcome shortfalls in commonly used, FDA-approved taxane therapies, such as paclitaxel and docetaxel, for treatment of an array of cancers. PGT technology utilizes a novel composition of a protein and a taxane without Cremophor or a linking group to improve the delivery method and target the chemotherapeutic agent to the tumor resulting in greater specificity without toxicity.

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceutical's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information

  • INVESTOR AND MEDIA CONTACT:
    OncBioMune Pharmaceuticals, Inc.
    Andrew Kucharchuk
    President and Chief Financial Officer
    akucharchuk@oncbiomune.com